Extended Spectrum ??-Lactamase (ESBL)-Producing Enterobacteriaceae
Authors:
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 63 (4) , 353-365
Abstract
Extended spectrum β-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10–40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs. ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading. Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC β-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by β-lactamase inhibitors such as clavulanic acid, the activity of β-lactam/β-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.Keywords
This publication has 95 references indexed in Scilit:
- Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99)Diagnostic Microbiology and Infectious Disease, 2002
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Summation: β-lactam resistance surveillance in the Asia–Western Pacific RegionDiagnostic Microbiology and Infectious Disease, 1999
- In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: role of fourth-generation cephalosporinsDiagnostic Microbiology and Infectious Disease, 1999
- In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: role of fourth-generation cephalosporinsDiagnostic Microbiology and Infectious Disease, 1999
- In vitro evaluation of cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centersDiagnostic Microbiology and Infectious Disease, 1999
- Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest methodDiagnostic Microbiology and Infectious Disease, 1999
- Concurrent outbreaks of extended-spectrum β-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospitalJournal of Antimicrobial Chemotherapy, 1999
- Broad-Spectrum, Transmissible β-LactamasesNew England Journal of Medicine, 1988
- TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAEThe Lancet, 1987